NasdaqGS:VRTXBiotechs
Vertex Pharmaceuticals (VRTX) Following Fresh CASGEVY Data Has Its Valuation Back In Focus
Vertex Pharmaceuticals (VRTX) is back in focus after fresh Phase 3 data for its gene editing therapy CASGEVY in children aged 5 to 11 with severe sickle cell disease and transfusion dependent beta thalassemia.
See our latest analysis for Vertex Pharmaceuticals.
Recent clinical headlines around CASGEVY and suzetrigine appear to have coincided with stronger interest in Vertex Pharmaceuticals, with a 10.15% 1 month share price return and a 137.47% 5 year total shareholder return suggesting...